Cargando…

Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients

BACKGROUND: Anaplastic Lymphoma Kinase (ALK) positivity represents a novel molecular target in a subset of Non-Small Cell Lung Cancers (NSCLC). We explore Fluorescence in situ Hybridization (FISH) and Immunohistochemistry (IHC) as diagnostic methods for ALK positive patients and to describe its prev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinez, Pablo, Hernández-Losa, Javier, Cedrés, Susana, Castellví, Josep, Martinez-Marti, Alex, Tallada, Natalia, Murtra-Garrell, Nuria, Navarro-Mendivill, Alejandro, Rodriguez-Freixinos, Victor, Canela, Mercedes, Ramon y Cajal, Santiago, Felip, Enriqueta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554741/ https://www.ncbi.nlm.nih.gov/pubmed/23359795 http://dx.doi.org/10.1371/journal.pone.0052261

Ejemplares similares

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC
por: Frigola, Joan, et al.
Publicado: (2022)

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
por: Cedrés, Susana, et al.
Publicado: (2015)

Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients
por: Callejo, Ana, et al.
Publicado: (2021)

Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
por: Cedres, Susana, et al.
Publicado: (2021)

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
por: Iranzo, Patricia, et al.
Publicado: (2022)

PI3K Pathway in NSCLC
por: Martinez-Martí, Alex, et al.
Publicado: (2012)

Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics
por: Ramón y Cajal, Santiago, et al.
Publicado: (2019)

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation
por: Cedrés, Susana, et al.
Publicado: (2018)

ALK Gene Rearrangements in Lung Adenocarcinomas: Concordance of Immunohistochemistry, Fluorescence In Situ Hybridization, RNA In Situ Hybridization, and RNA Next-Generation Sequencing Testing
por: Canterbury, Carleigh R., et al.
Publicado: (2021)

Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC
por: Carbonell, Caterina, et al.
Publicado: (2023)

Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Frigola, Joan, et al.
Publicado: (2021)

Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report
por: Zhang, Xiao-Ying, et al.
Publicado: (2023)

Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry
por: Conde, Esther, et al.
Publicado: (2014)

ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients
por: Uruga, Hironori, et al.
Publicado: (2018)

Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing
por: Jurmeister, Philipp, et al.
Publicado: (2021)

Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement
por: Shan, Ling, et al.
Publicado: (2014)

Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry
por: Wang, Jiandong, et al.
Publicado: (2014)

Two Cases of ALK-Altered Cancers of Unknown Primary Diagnosed by Immunohistochemistry
por: Kato, Yoriko, et al.
Publicado: (2022)

Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative
por: Ma, Di, et al.
Publicado: (2016)

Clinical implications of intratumor heterogeneity: challenges and opportunities
por: Ramón y Cajal, Santiago, et al.
Publicado: (2020)

Rectal Metastases from Squamous Cell Carcinoma: A Case Report and Review of the Literature
por: Cedrés, S., et al.
Publicado: (2012)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
por: Dienstmann, Rodrigo, et al.
Publicado: (2011)

Association of Alk1 and Endoglin Polymorphisms with Cardiovascular Damage
por: Garzon-Martinez, Mercedes, et al.
Publicado: (2020)

Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients
por: Cedres, Susana, et al.
Publicado: (2023)

Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics
por: Nassif, Samer, et al.
Publicado: (2019)

Beyond molecular tumor heterogeneity: protein synthesis takes control
por: Ramon y Cajal, Santiago, et al.
Publicado: (2018)

Combining Lipophilic dye, in situ Hybridization, Immunohistochemistry, and Histology
por: Duncan, Jeremy, et al.
Publicado: (2011)

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC
por: Noé, Johannes, et al.
Publicado: (2022)

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening
por: Lee, Jeeyun, et al.
Publicado: (2015)

miR-125b Acts as a Tumor Suppressor in Breast Tumorigenesis via Its Novel Direct Targets ENPEP, CK2-α, CCNJ, and MEGF9
por: Feliciano, Andrea, et al.
Publicado: (2013)

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)
por: Takeuchi, K., et al.
Publicado: (2016)

An Optimized Small Tissue Handling System for Immunohistochemistry and In Situ Hybridization
por: Anthony, Giovanni, et al.
Publicado: (2016)

Ovarian Fibrosarcoma: Clinicopathologic Considerations about the Intraoperative and Post-Surgical Procedures
por: García Jiménez, Angel, et al.
Publicado: (2009)

Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia
por: Plata, Adriana, et al.
Publicado: (2013)

Insight into the Role and Regulation of Gap Junction Genes in Lung Cancer and Identification of Nuclear Cx43 as a Putative Biomarker of Poor Prognosis
por: Aasen, Trond, et al.
Publicado: (2019)

Phosphorylation of eIF4E Confers Resistance to Cellular Stress and DNA-Damaging Agents through an Interaction with 4E-T: A Rationale for Novel Therapeutic Approaches
por: Martínez, Alba, et al.
Publicado: (2015)

Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required
por: Pickett, Justine L., et al.
Publicado: (2017)

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
por: Bauer, Todd M., et al.
Publicado: (2020)

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial
por: Kim, Dong-Wan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_23vbi3f6ooaap89omscojddq41